News

Richmond pharma company Kaléo Acquired

New York-based Marathon Asset Management LP announced it has entered into a definitive agreement to acquire Richmond-based privately held pharmaceutical company Kaléo Inc., which is known for treating allergic anaphylaxis and opioids overdoses.

The total base purchase price is approximately $310 million in cash, less certain adjustments and includes potential net revenue-based milestone payments of up to approximately $70 million in cash for the 2022 and 2023 fiscal years, in a transaction that will provide liquidity for Kaléo shareholders upon closing, according to a news release from Marathon.

“The sales trajectory of Kaléo has been impressive, and we view the company as a platform for growth,” Dr. Evan Bedil, Marathon’s head of healthcare, said in a statement. “We plan to leverage the company’s strong portfolio of intellectual property, its leading reputation among allergists and its experienced management team to pursue multiple avenues of growth in the coming years.”

The company’s headquarters will remain in Richmond.

Additionally, Richmond-based plastic films and aluminum extrusions manufacturer Tredegar Corp. is selling its 18% ownership stake in Kaléo, which is about 3.3 million shares, the company announced Monday. Tredegar is a 1989 spinoff of Ethyl Crop., which now operates as NewMarket Corp.

Twin brothers Dr. Eric Edwards and Evan Edwards founded Kaléo in 2005 and left in 2019. Eric Edwards co-founded Phlow Corp., another Richmond-based company developing new ways to manufacture essential medicines.

Phlow has plans to open a $125 million plant in Petersburg. In May 2020, Phlow was awarded a $354 million, four-year federal contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to produce the essential medications using advanced manufacturing processes from the Medicines for All Institute based at Virginia Commonwealth University’s College of Engineering.

Kaléo, which has more than 200 issued patents, developed the patented Aerio Auto-Injection Platform for treating allergic anaphylaxis and opioids overdoses. It also developed Evzio, a prescription medicine used to treat opioid emergencies, such as overdoses. The company commercialized the AUVI-Q epinephrine injector, which distributes 0.15 mg and 0.3 mg doses, and the AUVI-q, which injects 0.1 mg of epinephrine and is designed for infants and toddlers.

In 2020, Kaléo started offering its auto-injector under the name Allerject in Canada.

“Kaléo’s executive management team enthusiastically looks forward to joining forces with Marathon, which has been a strong ally of Kaléo as a lender for many years,” Kaléo President and CEO Ronald Gunn said in a statement. “With its vast resources and well-established capital base, we have found the strongest possible partner to help us commercialize our significant intellectual property and write the next chapter in Kaléo’s story.”

The Kaléo Board of Directors and shareholders have unanimously approved the transaction, which is expected to close on or before Dec. 31.

 

Read more here.

Recent News

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that